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Getting Stronger: The Relationship 
Between a newly Identified Virus  
and Merkel Cell Carcinoma
Christopher B. Buck1 and Douglas R. Lowy1
Merkel cell carcinoma (MCC) is an aggressive skin cancer that develops in individu-
als who are over the age of 50 or immunosuppressed. DnA from a new polyoma-
virus, MCPyV, was recently shown to be clonally integrated in several MCC cases. 
In this issue, Becker et al. demonstrate that MCPyV DnA can be isolated from 85% 
of primary European MCC specimens and their metastases, and Garneski et al. 
present data indicating that the percentage of Australian MCC cases containing 
MCPyV may be lower than that of north American cases. These reports support 
the possibility that MCPyV is etiologically involved in at least some cases of MCC.
Journal of Investigative Dermatology (2008), 129, 9–11. doi:10.1038/jid.2008.302
Earlier this year, genetic analysis of 
Merkel cell carcinomas (MCCs) revealed 
the existence of a previously unidentified 
human polyomavirus (Feng et al., 2008). 
DNA sequences from the virus, desig-
nated Merkel cell carcinoma polyoma-
virus (MCPyV), were detected in 8 of 
10 MCC tumor specimens but in only 
4 of 25 (16%) control skin samples. In 
this issue of the Journal of Investigative 
Dermatology, two letters confirm and 
significantly extend these findings to 
additional cases of MCC (Becker et al., 
2008; Garneski et al., 2008). Using PCR-
based analysis, Becker et al. found that 
45 of 53 (85%) MCC cases from a cen-
ter in Europe contained MCPyV DNA. 
Garneski et al. detected MCPyV DNA 
in 11 of 16 (69%) North American and 
5 of 21 (24%) Australian MCC speci-
mens. The frequent detection of MCPyV 
DNA in European cases of MCC was 
also recently confirmed by Kassem et al. 
(2008). The clear confirmation that most 
MCC tumors carry MCPyV sequences 
represents an important step in address-
ing the intriguing hypothesis that the 
virus is a key etiologic agent behind 
MCC and perhaps other forms of cancer.
clinical and epidemiological 
features of mcc
Merkel cells were identified in 1875 as a 
distinctive, histologically translucent cell 
type associated with epidermal nerve 
endings (Halata et al., 2003). At the 
time of their discovery, it was reasoned 
that Merkel cells might participate in the 
sensation of mechanical stimuli. Like 
melanocyte precursors, the precursors of 
Merkel cells are thought to migrate dur-
ing development from the neural crest to 
their ultimate home in the basal layer of 
the epidermis and the outer root sheath 
of hair follicles (Szeder et al., 2003). 
Although Merkel cells do exhibit a num-
ber of neuroendocrine features, such as 
cytoplasmic neuropeptide–containing 
granules, the idea that they are directly 
involved in mechanosensation remains 
inferential (Boulais and Misery, 2008).
Approximately 1,500 new MCC cases 
are diagnosed in the United States each 
year (Lemos and Nghiem, 2007). MCC is 
thus a rare form of skin cancer compared 
with the more than 1 million cases of 
nonmelanoma skin cancer and roughly 
60,000 cases of melanoma per year in 
the same population. However, MCC is 
an aggressive, fast-growing malignancy 
that ultimately kills about one-third of 
those diagnosed with the disease. It is also 
important to note an alarming threefold 
increase in the incidence of MCC between 
1986 and 2001 (Hodgson, 2005).
MCC is more common in lighter-
skinned individuals, is associated with a 
history of sun exposure, and occurs pre-
dominantly on sun-exposed areas, such 
as the face (especially around the eyes) 
and extremities (Miller and Rabkin, 1999). 
Limited mutational screening of cellular 
genes in MCC identified the presence of 
two C-to-T transitions, characteristic of 
UVB-induced mutation, in one MCC cell 
line (Van Gele et al., 2000). Garneski et 
al. (2008, this issue) speculate that the 
smaller percentage of MCPyV in the 
Australian MCC cases they studied (24% 
vs. 69% in the North American cases, 
P = 0.009) might be related to the greater 
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degree of sun exposure in the Australian 
population—thus leading to a greater 
fraction of MCPyV-independent MCC—
compared with the North American and 
European populations.
The MCC tumor typically presents as 
a firm, painless, nonpigmented nodule 
but may be pink to violet. As with kera-
toacanthomas, MCC tumors can grow 
rapidly over the course of as little as a 
few weeks. Ninety-five percent of MCC 
cases arise in individuals over the age 
of 50 (Goessling et al., 2002). Although 
the relative risk of MCC is dramatically 
increased in immuno compromised 
populations, such as organ-transplant 
recipients and patients with AIDS (Engels 
et al., 2002), the great majority of newly 
diagnosed MCC patients are not recog-
nized clinically as immuno compromised. 
It is conceivable, however, that the wan-
ing immunity typically associated with 
advancing age could be a contribu-
tory factor in the development of MCC 
in older individuals. Given the estab-
lished correlation between immunode-
ficiency and the occurrence of cancers 
with known viral etiology (for example, 
human herpesvirus-8–induced Kaposi’s 
sarcoma and human papillomavirus–
induced squamous cell cancers in epider-
modysplasia verruciformis and cervical 
cancer), the correlation between MCC 
and immuno deficiency can be seen as a 
possible clue indicating a viral etiology.
What are polyomaviruses?
MCPyV belongs to a diverse family of 
non-enveloped DNA viruses that infect 
various vertebrates. Several polyoma-
virus types, including BK and JC polyo-
mavirus, have long been known to 
infect human populations. Early clues 
had indicated the possible existence of 
unidentified MCPyV-related polyoma-
viruses in humans (Brade et al., 1981), 
and recent reports have identified addi-
tional human polyomaviruses from 
various phylogenetic branches of the 
family (reviewed in zur Hausen, 2008). 
Although polyomaviruses can induce 
malignant transformation in cultured cells 
and in animal models, links between pre-
viously identified human polyomaviruses 
and cancer have been tenuous at best. 
Thus, the apparently strong correlation 
between MCPyV and MCC has gener-
ated a significant resurgence of interest 
in the possible viral etiology of MCC and 
perhaps other cancer types.
What is the role of mcPyV in mcc?
As with much important research, the 
observation that most MCC tumors 
harbor MCPyV DNA raises important 
questions for subsequent studies. A criti-
cal question is whether MCPyV is an eti-
ological cause of MCC, as opposed to a 
mere hitchhiker in this type of tumor. The 
available data suggest that PCPyV will 
turn out to be pathogenetically involved 
in at least a fraction of MCC cases. Feng 
et al. (2008) reported clonal integration 
of PCPyV DNA in the host genome in 
six of the eight virus-positive tumors they 
studied, implying that the viral DNA was 
integrated early in the course of tumor 
development. Juergen et al. found that 
25 of 25 mestastases from virus-positive 
primary tumors contained MCPyV 
DNA, whereas 0 of 3 metastases from 
virus-negative primary tumors contained 
MCPyV DNA; these results strongly sug-
gest that the virus-positive metastases 
were derived from cells that harbored 
viral DNA in the primary tumors. It will be 
important for future studies to determine 
whether viral infection precedes tumor 
development, whether viral gene expres-
sion is required for tumor maintenance, 
and whether MCPyV is tumorigenic in 
experimental systems. If the viral DNA is 
necessary for maintenance of the malig-
nant phenotype, the development of 
targeted therapies against pathologically 
relevant viral genes would be a desirable 
goal. It would also be important to test 
whether MCPyV might be implicated in 
other tumor types and, perhaps, wheth-
er other polyomaviruses cause human 
tumors (zur Hausen, 2008).
Is mcPyV an animal virus  
or a human virus?
Another key question is whether MCPyV 
is endemic in the human population or 
primarily an animal polyomavirus for 
which humans are an accidental host. 
Partial support for the latter possibility 
is the finding that polyomavirus simian 
virus-40 does not appear to cause disease 
in its natural host, the rhesus monkey, 
but can cause experimental tumors in 
hetero logous hosts, such as hamsters. An 
alternative scenario is that MCPyV circu-
lates widely in human populations and 
simply causes few apparent symptoms in 
the great majority of infected individuals. 
A precedent for this scenario can be 
found in the epidemiology of epidermo-
dysplasia verruciformis–type human pap-
illomaviruses, which infect most humans 
asymptomatically worldwide but cause 
squamous cell carcinomas in only a 
small minority of infected individuals 
(Orth, 2005).
The search for answers to these ques-
tions and more will no doubt generate 
fertile areas of research in the years to 
come.
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The Complexity of  
Diagnosing Melanoma
Ashfaq A. Marghoob1 and Alon Scope1
Recognizing that a cure lies in timely detection, dermatologists strive to diagnose 
malignant melanoma (MM) at the earliest possible stage. The desire to achieve 
this goal without injudiciously and unnecessarily excising many benign lesions has 
led to numerous techniques that assist clinicians in differentiating nevi from MM, 
including clinical mnemonics and algorithms, optical imaging instruments, and 
computer-assisted diagnostic systems. Most of these seemingly diverse methods 
rely on evaluating the in vivo morphology of lesions. In this issue, Guitera et al. 
compare dermoscopy with reflectance confocal microscopy (RCM) in an attempt 
to determine which imaging modality facilitates accurate diagnosis of melano-
cytic lesions using diagnostic parameters such as sensitivity and specificity.
Journal of Investigative Dermatology (2009), 129, 11–13. doi:10.1038/jid.2008.388
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The study by Guitera et al. (2009, this 
issue) is an important step toward future 
use of RCM as a “bedside” diagnostic 
tool. At this juncture, we reflect on the 
framework of the clinical diagnosis of 
melanocytic lesions and where in vivo 
imaging tools fit into this framework. 
Although Guitera et al. have shown that 
RCM increased diagnostic accuracy 
over dermoscopy, such a comparison 
may be an oversimplification of what 
occurs in real life. Components of skin 
examination and diagnostic aids are not 
mutually exclusive; rather, they provide 
complementary information necessary 
for rendering a correct decision. For 
example, in the study by Guitera et al., 
eight MMs that were misdiagnosed via 
RCM were correctly diagnosed with 
dermoscopy. On the other hand, 12 
MMs that were incorrectly identified 
with dermoscopy were correctly diag-
nosed via RCM. When dermoscopy 
and RCM were used together, sensitiv-
ity was highest, with only three mela-
nomas incorrectly classified.
To judge whether an in vivo diag-
nostic technique is truly superior in 
terms of diagnostic accuracy, it is essen-
tial to account for the complexity of 
the clinical decision-making process. 
Components of the skin examination 
used in the evaluation of lesions include 
patient-derived anamnestic data, ana-
lytical reasoning, comparative recogni-
tion, differential recognition, and pattern 
analysis, which is also known as gestalt 
(see Figure 1; Gachon et al., 2005). This 
information can then be integrated with 
information obtained via diagnostic 
tools such as dermoscopy and RCM. In 
fact, experts “use multiple, combined 
strategies to solve clinical problems, 
suggesting a high degree of mental flex-
ibility and adaptability in clinical rea-
soning” (Norman, 2006). Experts’ ability 
to rapidly extract pertinent information 
from multiple sources has proven diffi-
cult for automated vision instruments to 
recreate. Thus, it is the evolving human 
cognitive process that allows clinicians 
to identify MM despite its varied clinical 
faces.
The ABCD mnemonic, introduced 
in 1985, represents an analytical meth-
od for the evaluation of MM and was 
probably the first method conveyed 
by experts to the dermatological com-
munity and later to the general pub-
lic. However, the ABCD method did 
not help to distinguish some dysplas-
tic nevi from MMs and failed to iden-
tify some MMs at an early stage (e.g., 
MMs with a small diameter). The intro-
duction of analytical algorithms that 
utilize dermoscopy—such as the ABCD 
method of dermoscopy, the seven-point 
checklist, and the Menzies method—
have improved discrimination but have 
not eliminated the challenge of clini-
cally distinguishing MMs from some 
nevi (Roesch et al., 2006).
In 1990, patient anamnestic data, 
which included both historical criteria 
(i.e., the presence of new or chang-
ing lesions) and lesion symptomology, 
were emphasized to help detect MM. 
Such patient-derived information was 
sensitive for MM identification and 
allowed the detection of an additional 
subset of MM that defies the ABCDs. 
Thus was born the Glasgow checklist. 
Similarly, “E,” for evolution, was subse-
quently added to the ABCD mnemonic. 
However, patient self-reporting has lim-
itations, and the need to further improve 
the detection of new and changing 
lesions brought about the introduc-
tion of baseline whole-body photogra-
phy and short-term dermoscopic mole 
monitoring in clinical practice—both of 
|RCM increases specificity above dermoscopic 
assessment alone.
